Minnesota FOIA #N006814116

Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

The award was issued by the Twin Cities entity to the University of California-Davis, located in Sacramento, California, USA. The contract amount is $90,000, awarded on December 27, 2019, for the procurement of Preemptive Rituximab to prevent recurrent FSGS after transplant. The vendor, University of California-Davis, is identified with supplier code 47386 and is based in Sacramento, CA. The purchase involved a single lot with a quantity of 1.0. The contract appears to be a one-time procurement with no specified multi-year or blanket arrangement. The award is relevant to the healthcare/medical research sector, specifically transplant research. No specific contacts or additional location details are provided beyond the supplier address in Sacramento. Likely competitors for similar awards could include pharmaceutical or biotech companies such as Genentech, Novartis, or Pfizer.

Description

Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant